|Chemical and physical data|
|Molar mass||314.354063 g/mol|
|3D model (Jmol)||Interactive image|
Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker. In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.
- Convergence Pharmaceuticals. "CNV1014802 - Convergence Pharmaceuticals".
- Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0.
- Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.
- MarketWatch (2014). "Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study".